Neumora Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q3 2022 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Neumora Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q3 2022 to Q3 2024.
  • Neumora Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $9.95M, a 54.2% increase year-over-year.
  • Neumora Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $36.1M.
  • Neumora Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $17.2M, a 108% increase from 2022.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $36.1M $9.95M +$3.5M +54.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 $32.6M $12.8M +$10.2M +402% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $22.4M $7.37M +$5.18M +236% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $17.2M $6.05M Oct 1, 2023 Dec 31, 2023 10-K 2024-03-07
Q3 2023 $6.45M +$4.35M +207% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $2.54M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $2.2M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q3 2022 $2.1M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.